In 2011, Antibiotice reported a net profit of RON20.5 million.
Overall revenue rose 5.4% in 2012 to RON327.4 million, while total costs inched up 3.8% RON295 million.
In 2013, Antibiotice forecasts 17% higher exports in 2013 from $20 million in 2012, fueled by expanded partnerships on the US market as well as on other countries.
The company’s majority holder is Romania’s Health Ministry, with a 53.02% stake, while investment fund SIF Oltenia (SIF5. RO) holds a 10.09% stake.
Antibiotice is the second-largest nystatin maker in the world, with a 35% market share, according to company information.
On the Bucharest market Wednesday, Antibiotice closed up 1.37% on the day at RON0.4450 a share. (EUR1=RON4.3779)